Halozyme Therapeutics (HALO) is soaring over 27.6% on the back of the company's pre-market...


Halozyme Therapeutics (HALO) is soaring over 27.6% on the back of the company's pre-market announcement that it had entered into a worldwide license agreement with Pfizer (PFE -1.1%).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs